摘要
文章通过对英国患者准入计划(Patient Access Scheme,PAS)实施及运行机制的综述,为创新药的医保准入及预案风险分担等相关政策制定提供参考。英国通过实施PAS,并在实践过程中不断优化运行机制,增加风险分担方案的多样性和灵活性,在支出可控的情况下提高了创新药的可负担性。我国在创新药医保快速准入方面可参考英国PAS的经验,构建国家层面卫生技术评估体系、尝试灵活多样的风险分担协议及拓宽多元筹资来源,进一步完善我国的创新药医保准入体系和多层次医疗保障体系。
Through a review of the implementation and operating mechanism of the Patient Access Scheme(PAS) in the UK,to provide references for the formulation of relevant policies for the medical insurance access and plan risk sharing of innovative drugs.By implementing PAS and optimizing the operational mechanisms in practice,the UK has increased the variety and flexibility of risk-sharing schemes to improve the affordability of innovative medicines while keeping expenditure under control.In light of faster access to innovative medicines,China should take the UK’s PAS experience as a reference to build a national health technology assessment system,use diverse risk-sharing agreements,and extend diverse financing sources for healthcare to further improve China’s reimbursement system of innovative medicines and multi-level medical insurance system.
作者
郭涛
刘跃华
张帆
刘昭
赵琨
GUO Tao;LIU Yue-hua;ZHANG Fan(China National Health Development Research Center,Beijing,100191,China;University of Duisburg-Essen,Essen,45117,Germany)
出处
《中国卫生经济》
北大核心
2021年第8期91-96,共6页
Chinese Health Economics
基金
2020年国家医疗保障局医疗保障事业管理中心委托项目。
关键词
创新药物
风险分担协议
卫生技术评估
患者准入计划
英国
innovative medicine
risk-sharing agreements
health technology assessment
patient access schemes
UK.
